<eesti>Ravimiseadus </eesti>
<inglise>Medicinal Products Act </inglise>
<eesti>Vastu v&otilde;etud 19. detsembril 1995. a. </eesti>
<inglise>Passed 19 December1995 </inglise>
<eesti>(RT I 1996, 3, 56), </eesti>
<inglise>(RT (1) I 1996, 3, 56), </inglise>
<eesti>j&otilde;ustunud 1. aprillil 1996.a., </eesti>
<inglise>entered into force 1 April 1996, </inglise>
<eesti>muudetud j&auml;rgmiste seadustega: </eesti>
<inglise>amended by the following Acts: </inglise>
<eesti>30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308; </eesti>
<inglise>30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308; </inglise>
<eesti>16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608; </eesti>
<inglise>16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608; </inglise>
<eesti>26.03.98 j&otilde;ust.03.05.98 - RT I 1998, 36/37, 554; </eesti>
<inglise>26.03.98 entered into force 03.05.98 - RT I 1998, 36/37, 554; </inglise>
<eesti>08.12.97 j&otilde;ust.01.01.98 - RT I 1997, 93, 1564; </eesti>
<inglise>08.12.97 entered into force 01.01.98 - RT I 1997, 93, 1564; </inglise>
<eesti>26.06.96 j&otilde;ust.26.07.96 - RT I 1996, 49, 954. </eesti>
<inglise>26.06.96 entered into force 26.07.96 - RT I 1996, 49, 954. </inglise>
<eesti>1. peat&uuml;kk </eesti>
<inglise>Chapter 1 </inglise>
<eesti>&Uuml;lds&auml;tted </eesti>
<inglise>General Provisions </inglise>
<eesti>&sect; 1. </eesti>
<inglise>&sect; 1. </inglise>
<eesti>Ravimiseaduse eesm&auml;rk ja &uuml;lesanded </eesti>
<inglise>Purpose of Medicinal Products Act </inglise>
<eesti>(1) Ravimiseadus m&auml;&auml;rab kindlaks ravimite tootmise, impordi, ekspordi ja turustamise korra. </eesti>
<inglise>(1) The Medicinal Products Act determines the procedures for the manufacture, import, export and marketing of medicinal products. </inglise>
<eesti>(2) K&auml;esolev seadus on aluseks teistele ravimite kohta k&auml;ivatele &otilde;igusaktidele. </eesti>
<inglise>(2) This Act is the basis for other legislation concerning medicinal products. </inglise>
<eesti>&sect; 2. </eesti>
<inglise>&sect; 2. </inglise>
<eesti>Ravimiseaduses kasutatavad m&otilde;isted </eesti>
<inglise>Definitions used in Medicinal Products Act </inglise>
<eesti>(1) Ravim on k&auml;esoleva seaduse t&auml;henduses igasugune aine, mis on m&otilde;eldud haiguse v&otilde;i haiguss&uuml;mptomi v&auml;ltimiseks, diagnoosimiseks, ravimiseks v&otilde;i haigusseisundi kergendamiseks inimesel v&otilde;i loomal, inimese v&otilde;i looma elutalituse taastamiseks v&otilde;i korrigeerimiseks. </eesti>
<inglise>(1) For the purposes of this Act, a medicinal product is any substance intended for the prevention, diagnosis or treatment of a disease or disease symptom, for the relief of a disease condition in a human or animal, or for the restoration or correction of vital functions in a human or animal. </inglise>
<eesti>(1 (1)) Ainult veterinaarias kasutatav ravim (edaspidi veterinaarravim) on k&auml;esoleva seaduse t&auml;henduses tootja poolt ainult loomadel kasutamiseks m&auml;&auml;ratud ravim, mis peab olema t&auml;histatud kirjega "veterinaarseks kasutamiseks". </eesti>
<inglise>(1 (1)) For the purposes of this Act, a medicinal product for use only in veterinary medicine (hereinafter veterinary medicinal product) is a medicinal product which is designated by the producer to be used only on animals and which shall be marked "veterinaarseks kasutamiseks" [ for veterinary use ]. </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(2) Ravimpreparaat on tootja originaalpakendis ravim, mis on valmistatud kasutamiseks ja turustamiseks. </eesti>
<inglise>(2) A proprietary medicinal product is a medicinal product in the original packaging of the manufacturer which is produced for use and marketing. </inglise>
<eesti>Ravimpreparaate, mis sisaldavad sama toimeainet erinevates kogustes v&otilde;i ravimvormides, k&auml;sitatakse kui erinevaid ravimpreparaate. </eesti>
<inglise>Proprietary medicinal products containing the same active ingredient in different quantities or different pharmaceutical forms are considered different proprietary medicinal products. </inglise>
<eesti>(3) Ravimisarnane aine on aine, milles on toimeainet koguses v&otilde;i vormis, mis ei luba teda pidada ravimiks, v&otilde;i mis ei sisalda &uuml;ldse toimeainet, kuid tootja v&otilde;i turustaja kirjeldab tootel ravimile iseloomulikke kasutusalasid. </eesti>
<inglise>(3) A semi-medicinal product is a product which contains an active ingredient in a quantity or form which does not allow it to be considered a medicinal product or which contains no active ingredient, but the manufacturer or marketer describes areas for use of the product which are characteristic of medicinal products. </inglise>
<eesti>(4) Toimeaine on teaduslike meetoditega m&auml;&auml;ratav aine, mida kasutatakse ravimina v&otilde;i ravimi koostisainena ja mis on m&otilde;eldud kasutamiseks k&auml;esoleva paragrahvi 1. l&otilde;ikes toodud eesm&auml;rkidel. </eesti>
<inglise>(4) An active ingredient is a substance determinable by scientific methods which is used as a medicinal product or as an ingredient in a medicinal product and is intended for use for the purposes specified in subsection (1) of this section. </inglise>
<eesti>(4 (1)) Ravims&ouml;&ouml;t on tema ravi- v&otilde;i haigust &auml;rahoidvate omaduste t&otilde;ttu loomade s&ouml;&ouml;tmiseks kasutatav ravimi ja s&ouml;&ouml;da segu. </eesti>
<inglise>(4 (1)) Medicated feedingstuffs are a mixture of medicinal products and feedingstuffs used for the feeding of animals due to the therapeutic or preventive characteristics thereof. </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(5) K&auml;esolevas seaduses nimetatakse ravimpreparaate ja ravimisarnaseid aineid ravimiteks ja k&auml;esoleva seaduse s&auml;tted kehtivad nende k&otilde;ikide kohta, kui pole kehtestatud teisiti. </eesti>
<inglise>(5) In this Act, proprietary medicinal products and semi-medicinal products are referred to as medicinal products, and the provisions of this Act apply to all such products unless established otherwise. </inglise>
<eesti>(6) Ravimite tootmine on k&auml;esoleva seaduse t&auml;henduses ravimite valmistamine, pakendamine v&otilde;i &uuml;mberpakendamine. </eesti>
<inglise>(6) For the purposes of this Act, the manufacture of medicinal products is the production, packaging or repackaging of medicinal products. </inglise>
<eesti>&sect; 3. </eesti>
<inglise>&sect; 3. </inglise>
<eesti>Ravimitele esitatavad n&otilde;uded </eesti>
<inglise>Requirements set for medicinal products </inglise>
<eesti>(1) K&otilde;ik ravimid peavad olema eeldatavate tarbimisomadustega ja nende eesm&auml;rgip&auml;rasel kasutamisel ohutud tarbija tervisele. </eesti>
<inglise>(1) All medicinal products shall have the presumed characteristics of use and be safe for the health of the consumer when used for their intended purpose. </inglise>
<eesti>Veterinaarias kasutatav ravim peab olema ohutu ka loomse saaduse kasutaja tervisele. </eesti>
<inglise>A medicinal product for use in veterinary medicine shall also be safe for the health of the consumer of the animal product. </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(2) Eestis v&otilde;ib turustada ja kasutada ainult Ravimiametis registreeritud ravimeid ja ravimeid, millele Ravimiamet on v&auml;ljastanud &uuml;hekordse impordi- ja kasutamisloa. </eesti>
<inglise>(2) Only medicinal products registered in the Agency of Medicines and medicinal products for which the Agency of Medicines has issued a single authorisation for import and use may be marketed and used in Estonia. </inglise>
<eesti>(3) Ravimite turustamisel peab nendega kaasas olema ammendav eestikeelne informatsioon ravimi koostise, koostisainete omavahelise vahekorra ja kasutamise kohta, kui sotsiaalminister pole kehtestanud teisiti. </eesti>
<inglise>(3) In marketing a medicinal product, the product shall be accompanied by exhaustive information in Estonian concerning the composition, proportions of the ingredients and use of the medicinal product, unless otherwise established by the Minister of Social Affairs. </inglise>
<eesti>(4) Ravimi nimetus ja kujundus ei tohi koostist ja &uuml;ldisi toimeid silmas pidades olla eksitav ning peab tagama tema eristamise teistest ravimitest. </eesti>
<inglise>(4) The name and design of a medicinal product shall not be misleading with regard to its composition or general effects and shall ensure the distinguishability of the product from other medicinal products. </inglise>
<eesti>Ravimiametil on &otilde;igus n&otilde;uda ravimile t&auml;iendava hoiatava erimarkeeringu paigutamist. </eesti>
<inglise>The Agency of Medicines has the right to require additional special precautionary labelling on a product. </inglise>
<eesti>(5) Ravimi registreerimiseks peab see vastama k&auml;esoleva paragrahvi 1., 3. ja 4. l&otilde;ikes toodud n&otilde;uetele. </eesti>
<inglise>(5) A medicinal product must meet the requirements specified in subsections (1), (3) and (4) of this section in order to be registered. </inglise>
<eesti>&sect; 4. </eesti>
<inglise>&sect; 4. </inglise>
<eesti>Seosed teiste seadustega </eesti>
<inglise>Relations with other Acts </inglise>
<eesti>(1) K&auml;esolevas seaduses k&auml;sitletud ravimitele, mis kuuluvad narkootiliste ainete hulka, laienevad narkootiliste ainete kohta k&auml;ivad seadused ja muud &otilde;igusaktid. </eesti>
<inglise>(1) Acts and other legislation concerning narcotic substances extend to medicinal products which are classified as narcotic substances and are governed by this Act. </inglise>
<eesti>(2) (Kehtetu - 16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(2) (Repealed - 16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(3) Radioaktiivsetele ravimitele laienevad radioaktiivsete ainete kohta k&auml;ivad seadused ja muud &otilde;igusaktid. </eesti>
<inglise>(3) Acts and other legislation concerning radioactive substances extend to radioactive medicinal products. </inglise>
<eesti>&sect; 5. </eesti>
<inglise>&sect; 5. </inglise>
<eesti>Vabariigi Valitsuse, sotsiaalministri, p&otilde;llumajandusministri ja Ravimiameti p&auml;devus </eesti>
<inglise>Competence of the Government of the Republic, Minister of Social Affairs, Minister of Agriculture and Agency of Medicines </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(1) Vabariigi Valitsus kehtestab ravimite tootmise, hulgi- ja jaem&uuml;&uuml;gi tegevusloa saamise n&otilde;uded, tegevusloa taotlemise ja t&uuml;histamise korra. </eesti>
<inglise>(1) The Government of the Republic shall establish the requirements for issue of an activity licence for the manufacture, wholesale or retail trade of medicinal products and the procedure for application for and revocation of an activity licence. </inglise>
<eesti>(2) Vabariigi Valitsus kehtestab ravimite hulgi- ja jaem&uuml;&uuml;gi juurdehindluse piirm&auml;&auml;rad ja nende rakendamise korra. </eesti>
<inglise>(2) The Government of the Republic shall establish the gross margins for wholesale and retail trade of medicinal products and the procedure for their implementation. </inglise>
<eesti>(3) Sotsiaalminister kehtestab ravimite hulgi- ja jaem&uuml;&uuml;gi, ravimite, sealhulgas veterinaarravimite, registreerimise, ravimitealase arvestuse ja aruandluse ning andmete avalikustamise korra. </eesti>
<inglise>(3) The Minister of Social Affairs shall establish the procedures for wholesale and retail trade of medicinal products, including veterinary medicinal products, registration of medicinal products, including veterinary medicinal products, recording and reporting regarding medicinal products and disclosure of data. </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(4) Sotsiaalminister kehtestab ravimite, sealhulgas veterinaarravimite, tootmise, impordi ja ekspordi eeskirjad ning sellekohase arvestuse ja aruandluse korra. </eesti>
<inglise>(4) The Minister of Social Affairs shall establish the rules for the manufacture, import and export of medicinal products, including veterinary medicinal products, and the procedures for related recording and reporting. </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(5) Sotsiaalminister annab koosk&otilde;las k&auml;esoleva seadusega v&auml;lja ravimite, sealhulgas veterinaarravimite, loetelusid ja eeskirju, mis puudutavad registreerimistaotlusega kaasask&auml;ivat dokumentatsiooni ning ravimpreparaadi v&otilde;i ravimisarnase aine koostise, pakendi v&otilde;i markeeringu muutmisega kaasnevaid protseduure. </eesti>
<inglise>(5) The Minister of Social Affairs shall in accordance with this Act issue lists of medicinal products, including veterinary medicinal products, and rules concerning supporting documentation for applications for registration and concerning procedures for variations to the composition, packaging or labelling of a proprietary medicinal product or semi-medicinal product. </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(5 (1)) Sotsiaalminister koosk&otilde;lastab k&auml;esoleva seaduse alusel v&auml;ljaantavad &otilde;igusaktid veterinaarias kasutatavaid ravimeid k&auml;sitlevas osas p&otilde;llumajandusministriga. </eesti>
<inglise>(5 (1)) The Minister of Social Affairs shall obtain approval from the Minister of Agriculture for the parts of legislation passed on the basis of this Act which concern medicinal products for use in veterinary medicine. </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(5 (2)) P&otilde;llumajandusminister kehtestab koosk&otilde;lastatult sotsiaalministriga: </eesti>
<inglise>(5 (2)) The Minister of Agriculture shall establish, with the approval of the Minister of Social Affairs: </inglise>
<eesti>1) (Kehtetu - 30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>1) (Repealed - 30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>2) p&otilde;llumajandusloomade suhtes kasutamiseks keelatud biostimulaatorite, hormoonpreparaatide ja muude ainete nimekirja; </eesti>
<inglise>2) a list of biostimulants, hormone preparations and other substances prohibited to be used on farm animals; </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>3) ravims&ouml;&ouml;tade tootmise n&otilde;uded, ravims&ouml;&ouml;tade impordi tingimused ja korra, tunnustamise ja registreerimise tingimused ja korra ning hulgi- ja jaem&uuml;&uuml;gi eeskirjad. </eesti>
<inglise>3) requirements on the production of medicated feedingstuffs, the conditions and procedure for import thereof, the conditions and procedure for approval and registration thereof, and rules for the wholesale trade and retail sale thereof. </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(5 (3)) P&otilde;llumajandusminister kehtestab ravimite ja ravims&ouml;&ouml;tade loomahaiguste ennetamiseks ja raviks kasutamise tingimused ja korra. </eesti>
<inglise>(5 (3)) The Minister of Agriculture shall establish the conditions and procedure for the use of medicinal products and medicated feedingstuffs for the prevention and treatment of animal disease. </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(6) Ravimite registreerimist ja ravimite kvaliteedi kontrolli korraldab ja selle eest vastutab Ravimiamet. </eesti>
<inglise>(6) The Agency of Medicines administers and is responsible for registration of medicinal products and quality control of medicinal products. </inglise>
<eesti>(7) Ravimiamet v&auml;ljastab ravimitootjatele ja hulgim&uuml;&uuml;giettev&otilde;tetele ravimite m&uuml;&uuml;gilubasid, ravimite impordi- v&otilde;i ekspordilubasid ning kontrollib narkootiliste ja ps&uuml;hhotroopsete ravimite importi, eksporti, s&auml;ilitamist ja kasutamist. </eesti>
<inglise>(7) The Agency of Medicines issues marketing authorisations and import and export licences for medicinal products to manufacturers and wholesalers of medicinal products and inspects the import, export, storage and use of narcotic and psychotropic medicinal products. </inglise>
<eesti>(8) Ravimiameti &uuml;lesandeks on ravimite registreerimistaotlustele eksperdihinnangute andmine ja ravimite keemilis-farmatseutiliste omaduste kontroll. </eesti>
<inglise>(8) The function of the Agency of Medicines is to provide expert assessments regarding applications for registration of medicinal products and to inspect the chemical and pharmaceutical characteristics of medicinal products. </inglise>
<eesti>(9) Ravimiametil on &otilde;igus otsustada, kas toode on ravim v&otilde;i mitte, ning vajadusel m&auml;&auml;ratleda, kas preparaat kuulub narkootiliste v&otilde;i ps&uuml;hhotroopsete ravimite hulka. </eesti>
<inglise>(9) The Agency of Medicines has the right to decide whether a product is a medicinal product and, if necessary, to classify a preparation as a narcotic or psychotropic medicinal product. </inglise>
<eesti>(10) Ravimiametil on &otilde;igus n&otilde;uda ravimitega tegelevatelt isikutelt informatsiooni nende ametialase tegevuse kohta ning kontrollida k&otilde;ikide ravimite ja teiste meditsiiniotstarbeliste toodete valmistamist, s&auml;ilitamist, turustamist ja muul viisil v&auml;ljastamist ning kontrollida selle kohta k&auml;ivat dokumentatsiooni. </eesti>
<inglise>(10) The Agency of Medicines has the right to demand information from persons dealing with medicinal products concerning their professional activities, to inspect the production, storage, marketing and distribution in any other manner of all medicinal products and other products for medical purposes, and to inspect related documentation. </inglise>
<eesti>Avastatud rikkumiste korral on Ravimiametil &otilde;igus teha ettekirjutusi rikkumiste k&otilde;rvaldamiseks. </eesti>
<inglise>The Agency of Medicines has the right to issue precepts for the elimination of discovered violations. </inglise>
<eesti>2. peat&uuml;kk </eesti>
<inglise>Chapter 2 </inglise>
<eesti>Ravimite tootmine, import ja eksport </eesti>
<inglise>Manufacture, Import and Export of Medicinal Products </inglise>
<eesti>&sect; 6. </eesti>
<inglise>&sect; 6. </inglise>
<eesti>Ravimite tootmine </eesti>
<inglise>Manufacture of medicinal products </inglise>
<eesti>(1) Ravimeid on lubatud toota ainult isikutel, kellel on Sotsiaalministeeriumi v&auml;ljaantud ravimite tootmise tegevusluba. </eesti>
<inglise>(1) Only persons who hold an activity licence issued by the Ministry of Social Affairs for the manufacture of medicinal products are permitted to manufacture medicinal products. </inglise>
<eesti>Ravimeid tootvas ettev&otilde;ttes peab t&ouml;&ouml;tama ravimite kvaliteedi kontrolli eest vastutav erialase ettevalmistusega isik. </eesti>
<inglise>An enterprise manufacturing medicinal products shall employ a person with professional qualifications who is responsible for quality control of medicinal products. </inglise>
<eesti>(2) Apteekidel on &otilde;igus ja kohustus valmistada ravimeid ekstemporaalselt ainult arstiretsepti alusel v&otilde;i Ravimiameti loal vastavalt sotsiaalministri kinnitatud eeskirjadele. </eesti>
<inglise>(2) Pharmacies have the right and the obligation to prepare medicinal products as magistral formulae only pursuant to a medical prescription or with the permission of the Agency of Medicines, pursuant to rules approved by the Minister of Social Affairs. </inglise>
<eesti>(3) Ravimite tootmisel v&otilde;ib kasutada aineid, mille omadused, puhtus ja koostis on m&auml;&auml;ratud kehtivate farmakop&ouml;ade v&otilde;i teiste eeskirjadega. </eesti>
<inglise>(3) Substances whose characteristics, purity and composition are specified in valid pharmacopoeias or by other rules shall be used in the manufacture of medicinal products. </inglise>
<eesti>(4) Ravimeid tootva ettev&otilde;tte juht vastutab k&auml;esoleva paragrahvi 3. l&otilde;ikes kehtestatud n&otilde;uetest ja ravimite kohta k&auml;ivatest teistest &otilde;igusaktidest kinnipidamise eest. </eesti>
<inglise>(4) The head of an enterprise manufacturing medicinal products is responsible for compliance with the requirements specified in subsection (3) of this section and other legislation concerning medicinal products. </inglise>
<eesti>(5) &Uuml;hel isikul v&otilde;ib samaaegselt olla ainult &uuml;ks j&auml;rgmistest tegevuslubadest: ravimite tootmise, hulgim&uuml;&uuml;gi v&otilde;i jaem&uuml;&uuml;gi tegevusluba. </eesti>
<inglise>(5) A person may concurrently hold only one of the following activity licences: an activity licence for the manufacture, wholesale or retail trade of medicinal products. </inglise>
<eesti>&sect; 7. </eesti>
<inglise>&sect; 7. </inglise>
<eesti>Ravimite import ja eksport </eesti>
<inglise>Import and export of medicinal products </inglise>
<eesti>(1) Ravimeid v&otilde;ib Eesti Vabariiki sisse tuua Eestis ravimeid tootev ettev&otilde;te oma toodangu valmistamiseks ja ettev&otilde;te, millel on Sotsiaalministeeriumi v&auml;ljaantud tegevusluba ravimite hulgim&uuml;&uuml;giks. </eesti>
<inglise>(1) Medicinal products may be imported into the Republic of Estonia by an enterprise manufacturing medicinal products in Estonia for manufacture of the production of the enterprise or by an enterprise which holds an activity licence issued by the Ministry of Social Affairs for wholesale trade of medicinal products. </inglise>
<eesti>(2) Ravimeid v&otilde;ib Eesti Vabariigist v&auml;lja viia Eestis ravimeid tootev ettev&otilde;te oma toodangu ulatuses ja ettev&otilde;te, millel on Sotsiaalministeeriumi v&auml;ljaantud tegevusluba ravimite hulgim&uuml;&uuml;giks. </eesti>
<inglise>(2) Medicinal products may be exported from the Republic of Estonia by an enterprise manufacturing medicinal products in Estonia, within the extent of its production, or by an enterprise which holds an activity licence issued by the Ministry of Social Affairs for wholesale trade of medicinal products. </inglise>
<eesti>(3) Eestisse saabuv ja Eestist lahkuv f&uuml;&uuml;siline isik v&otilde;ib kaasa v&otilde;tta ravimeid, mida ta kasutab meditsiinilisel eesm&auml;rgil isiklikuks v&otilde;i temaga kaasasolevate loomade tarbeks. </eesti>
<inglise>(3) A natural person arriving in or departing from Estonia may carry with him or her medicinal products for his or her personal medical use or for medical use on animals accompanying him or her. </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(4) Raviasutus v&otilde;ib ravimeid importida ainult sotsiaalministri kehtestatud korras ja Ravimiameti &uuml;hekordsel loal. </eesti>
<inglise>(4) A medical institution may only import medicinal products pursuant to procedure established by the Minister of Social Affairs and upon a single permission by the Agency of Medicines. </inglise>
<eesti>(5) Ravimeid v&otilde;ib importida teadust&ouml;&ouml;ks ka muu asutus sotsiaalministri kehtestatud korras Ravimiameti &uuml;hekordsel loal tingimusel, et ravimeid ei kasutata meditsiinilisel eesm&auml;rgil. </eesti>
<inglise>(5) Other institutions may also import medicinal products for scientific purposes pursuant to procedure established by the Minister of Social Affairs and upon a single permission by the Agency of Medicines on the condition that the medicinal products are not used for medical purposes. </inglise>
<eesti>(6) Ravimiametis registreerimata ravimeid v&otilde;ib importida ravimi v&auml;ljakirjutamis&otilde;igust omava arsti v&otilde;i veterinaararsti meditsiiniliselt p&otilde;hjendatud kirjalikul taotlusel tema poolt ravitava inimese v&otilde;i looma raviks Ravimiameti v&auml;ljastatud &uuml;hekordse impordiloa alusel. </eesti>
<inglise>(6) Medicinal products not registered with the Agency of Medicines may be imported, on the basis of a single authorisation for import of the Agency of Medicines, at the medically justified written request of a doctor or veterinarian qualified to prescribe the medicinal product for the treatment of a person or animal treated by the doctor or veterinarian. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>(7) Ravimi v&auml;ljakirjutamis&otilde;igust omav arst v&otilde;i veterinaararst esitab Ravimiametis registreerimata ravimi impordi taotlemiseks Ravimiametile j&auml;rgmised dokumendid ja andmed: </eesti>
<inglise>(7) In order to apply for the import of a medicinal product not registered with the Agency of Medicines, a doctor or veterinarian qualified to prescribe the medicinal product shall submit the following documents and information to the Agency of Medicines: </inglise>
<eesti>1) taotlus, milles m&auml;rgitakse taotleja nimi, t&ouml;&ouml;koht, t&ouml;&ouml;koha asukoht ja aadress, ametikoht, sidevahendite numbrid, kuup&auml;ev, allkiri; </eesti>
<inglise>1) an application which sets out the name and place of employment of the applicant, the seat and address of the place of employment, the position and telecommunications numbers of the applicant, the date and signature; </inglise>
<eesti>2) ravimi nimetus, toimeaine nimetus, ravimvorm ja tugevus, manustamisviis, pakendi suurus, ravimitootja, imporditav kogus; </eesti>
<inglise>2) the name of the medicinal product, name of the active ingredient, pharmaceutical form and strength, route of administration, the size of packaging, manufacturer of the medicinal product and the quantity to be imported; </inglise>
<eesti>3) meditsiiniline p&otilde;hjendus ravimi kasutamise vajaduse kohta; </eesti>
<inglise>3) medical justification of the need to use the medicinal product; </inglise>
<eesti>4) ravimi k&auml;ttetoimetamiseks vajalikud andmed; </eesti>
<inglise>4) information needed for the delivery of the medicinal product; </inglise>
<eesti>5) v&otilde;imalusel ravimi importija. </eesti>
<inglise>5) the importer of the medicinal product, if possible. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>(8) Ravimiamet kontrollib taotleja esitatud andmeid ja dokumente ning teeb otsuse Ravimiametis registreerimata ravimi impordi &otilde;igustatuse v&otilde;i mitte&otilde;igustatuse kohta 30 kalendrip&auml;eva jooksul k&auml;esoleva paragrahvi l&otilde;ikes 7 nimetatud dokumentide ja andmete Ravimiametile esitamisest alates. </eesti>
<inglise>(8) The Agency of Medicines shall verify the information and documents submitted by the applicant and decide whether import of the medicinal product not registered with the Agency of Medicines is justified or not justified within thirty calendar days as of the date of filing the documents and information specified in subsection (7) of this section with the Agency of Medicines. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>(9) Ravimiamet teeb otsuse Ravimiametis registreerimata ravimi impordi &otilde;igustamatuse kohta, kui: </eesti>
<inglise>(9) The Agency of Medicines shall decide that import of the medicinal product not registered with the Agency of Medicines is not justified if: </inglise>
<eesti>1) taotleja ei ole esitanud k&auml;esoleva paragrahvi l&otilde;ikes 7 nimetatud dokumente ja andmeid; </eesti>
<inglise>1) the applicant fails to submit documents and information specified in subsection (7) of this section; </inglise>
<eesti>2) ravimi kvaliteet ja efektiivsus ei ole t&otilde;endatud; </eesti>
<inglise>2) the quality and efficacy of the medicinal product has not been proved; </inglise>
<eesti>3) ravimi kasutamine v&otilde;ib olla ohtlik inimese v&otilde;i looma tervisele; </eesti>
<inglise>3) use of the medicinal product may be harmful to the health of the person or animal; </inglise>
<eesti>4) ravimi kasutamine raviks ei ole meditsiiniliselt p&otilde;hjendatud; </eesti>
<inglise>4) use of the medicinal product for treatment is not medically justified; </inglise>
<eesti>5) taotleja esitab teadlikult valeandmeid. </eesti>
<inglise>5) the applicant knowingly submits false information. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>(10) Kui Ravimiameti hinnangul on Ravimiametis registreerimata ravimi import &otilde;igustatud, v&auml;ljastab Ravimiameti peadirektor ravimi hulgim&uuml;&uuml;gi tegevusluba omavale isikule ravimi &uuml;hekordse impordiloa. </eesti>
<inglise>(10) If, in the opinion of the Agency of Medicines, the import of a medicinal product not registered with the Agency of Medicines is justified, the Director General of the Agency of Medicines shall issue a single authorisation to import the medicinal product to a person who holds an activity licence for wholesale trade in the medicinal product. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>(11) K&auml;esoleva paragrahvi l&otilde;igetes 1 ja 4 nimetatud isikud v&otilde;ivad importida ravimeid ravimi kliinilise uuringu l&auml;biviimiseks Ravimiameti peadirektori n&otilde;usolekul. </eesti>
<inglise>(11) Persons specified in subsections (1) and (4) of this section may import medicinal products in order to conduct clinical trials of medicinal products with the consent of the Director General of the Agency of Medicines. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>3. peat&uuml;kk </eesti>
<inglise>Chapter 3 </inglise>
<eesti>Ravimite turustamine ja registreerimine </eesti>
<inglise>Marketing and Registration of Medicinal Products </inglise>
<eesti>&sect; 8. </eesti>
<inglise>&sect; 8. </inglise>
<eesti>Ravimite hulgim&uuml;&uuml;k </eesti>
<inglise>Wholesale trade of medicinal products </inglise>
<eesti>(1) Ravimeid v&otilde;ivad hulgi m&uuml;&uuml;a ainult Eesti Vabariigis kehtivat ravimite tootmise tegevusluba omavad tootjad oma toodangu ulatuses ja ettev&otilde;tted, millel on Sotsiaalministeeriumi v&auml;ljaantud ravimite hulgim&uuml;&uuml;gi tegevusluba. </eesti>
<inglise>(1) Only a manufacturer who holds an activity licence valid in the Republic of Estonia for the manufacture of medicinal products, within the extent of the manufacturer's production, or an enterprise which holds an activity licence issued by the Ministry of Social Affairs for wholesale trade of medicinal products may wholesale medicinal products. </inglise>
<eesti>(2) Ravimite hulgim&uuml;&uuml;gi korras v&otilde;ib ravimeid m&uuml;&uuml;a apteegile, ravimeid tootvale ettev&otilde;ttele ja vastavat tegevusluba omavale hulgim&uuml;&uuml;giettev&otilde;ttele ning asutustele, mille nimekirja kinnitab sotsiaalminister. </eesti>
<inglise>(2) Medicinal products may be sold wholesale to pharmacies, enterprises manufacturing medicinal products, wholesalers who hold a corresponding activity licence and institutions in a list approved by the Minister of Social Affairs. </inglise>
<eesti>Ravimite hulgim&uuml;&uuml;giettev&otilde;te v&otilde;ib hankida ravimeid ainult neid tootvast ettev&otilde;ttest, teisest ravimite hulgim&uuml;&uuml;gi ettev&otilde;ttest v&otilde;i apteegist. </eesti>
<inglise>A wholesaler of medicinal products may only procure medicinal products from an enterprise manufacturing medicinal products, another wholesaler of medicinal products or a pharmacy. </inglise>
<eesti>Veterinaarseks kasutamiseks v&otilde;ib ravimite hulgim&uuml;&uuml;gi korras m&uuml;&uuml;a ravimeid ka isikule, kes omab kehtivat tegevusluba veterinaarteenuse osutamiseks. </eesti>
<inglise>Medicinal products for use in veterinary medicine may also be sold wholesale to a person holding a valid activity licence for the provision of veterinary services. </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(3) Ravimite hulgim&uuml;&uuml;giettev&otilde;tte juht vastutab, et ettev&otilde;ttest m&uuml;&uuml;davad ravimid vastaksid k&auml;esolevas seaduses ja teistes &otilde;igusaktides esitatud n&otilde;uetele ja et peetaks kinni ravimite s&auml;ilitamise eeskirjadest, n&otilde;uetekohasest arvepidamisest ja ravimitealastest &otilde;igusaktidest. </eesti>
<inglise>(3) The head of a wholesaler of medicinal products is responsible for compliance of the medicinal products sold by the enterprise with the requirements set in this Act and other legislation, for compliance with the rules concerning storage of medicinal products, recording requirements and legislation governing medicinal products. </inglise>
<eesti>(4) Hulgim&uuml;&uuml;giettev&otilde;te on kohustatud tagasi ostma ning n&otilde;uetekohasel viisil kahjutuks tegema tema poolt v&auml;ljastatud ebakvaliteetsed ravimid. </eesti>
<inglise>(4) A wholesaler is required to repurchase and, in the required manner, safely dispose of substandard medicinal products distributed by the wholesaler. </inglise>
<eesti>&sect; 9. </eesti>
<inglise>&sect; 9. </inglise>
<eesti>Ravimite jaem&uuml;&uuml;k </eesti>
<inglise>Retail trade of medicinal products </inglise>
<eesti>(1) Ravimite jaem&uuml;&uuml;k elanikele ja ekstemporaalne valmistamine on lubatud ainult apteegis. </eesti>
<inglise>(1) Retail trade of medicinal products to the public and preparation of medicinal products as magistral formulae are permitted only in a pharmacy. </inglise>
<eesti>(2) Apteek v&otilde;ib ravimeid hankida ainult k&auml;esoleva seaduse paragrahv 8 l&otilde;ikes 1 loetletud ettev&otilde;tetest v&otilde;i teisest apteegist. </eesti>
<inglise>(2) A pharmacy may only procure medicinal products from enterprises specified in subsection 8 (1) of this Act or other pharmacies. </inglise>
<eesti>(3) Apteek v&otilde;ib m&uuml;&uuml;a ainult k&auml;esoleva seaduse paragrahv 3 l&otilde;ikes 2 toodud n&otilde;uetele vastavaid ravimeid ja samas apteegis k&auml;esoleva seaduse paragrahv 6 l&otilde;ikes 2 toodud tingimustel valmistatud ravimeid. </eesti>
<inglise>(3) A pharmacy may only sell medicinal products which meet the requirements specified in subsection 3 (2) of this Act and medicinal products prepared in the same pharmacy under the conditions specified in subsection 6 (2) of this Act. </inglise>
<eesti>Retseptiravimit v&otilde;ib m&uuml;&uuml;a ainult n&otilde;uetekohase retsepti alusel. </eesti>
<inglise>A prescription medicinal product may only be sold pursuant to a valid prescription. </inglise>
<eesti>(4) Ravimi v&auml;ljastamisel apteegist tuleb ravimi saajat informeerida ravimi &otilde;igest ja ohutust tarvitamisest. </eesti>
<inglise>(4) Upon dispensation of a medicinal product from a pharmacy, the recipient of the medicinal product shall be informed of the correct and safe use of the medicinal product. </inglise>
<eesti>(5) Apteegis v&otilde;ib m&uuml;&uuml;a lisaks ravimitele teisi meditsiiniotstarbelisi tooteid (h&uuml;gieeni-, desinfektsiooni-, haigep&otilde;etusvahendeid jmt.) tingimusel, et nende m&uuml;&uuml;k ei takista ravimite m&uuml;&uuml;ki. </eesti>
<inglise>(5) In addition to medicinal products, pharmacies may sell other products for medical purposes (toiletries, disinfectants, medical supplies, etc.) on the condition that the sale of such products does not hinder the sale of medicinal products. </inglise>
<eesti>(6) Sotsiaalminister kehtestab apteekidest ravimite v&auml;ljastamise eeskirjad. </eesti>
<inglise>(6) The Minister of Social Affairs shall establish the rules for dispensation of medicinal products from pharmacies. </inglise>
<eesti>&sect; 10. </eesti>
<inglise>&sect; 10. </inglise>
<eesti>Apteek </eesti>
<inglise>Pharmacy </inglise>
<eesti>(1) Apteek on ettev&otilde;te, mille tegevuse eeskirjad, asutamise ja sulgemise korra kehtestab sotsiaalminister. </eesti>
<inglise>(1) A pharmacy is an enterprise whose operational rules and procedures for foundation and termination shall be established by the Minister of Social Affairs. </inglise>
<eesti>(1 (1)) Veterinaarapteek on apteek, millel on &otilde;igus v&auml;ljastada ainult veterinaarravimeid ja millel ei ole ravimite ekstemporaalse valmistamise kohustust. </eesti>
<inglise>(1 (1)) A veterinary pharmacy is a pharmacy which has the right to dispense only veterinary medicinal products and which has no obligation to prepare medicinal products as magistral formulae. </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(2) Haruapteek ja apteegi m&uuml;&uuml;gipunkt on apteegi allasutused. </eesti>
<inglise>(2) A branch pharmacy and a pharmacy counter are subsidiaries of a pharmacy. </inglise>
<eesti>Apteegil on &otilde;igus avada &uuml;ks haruapteek ja kaks apteegi m&uuml;&uuml;gipunkti. </eesti>
<inglise>A pharmacy has the right to open one branch pharmacy and two pharmacy counters. </inglise>
<eesti>Haruapteegi ja apteegi m&uuml;&uuml;gipunkti tegevuse eest vastutab apteegi juhataja. </eesti>
<inglise>The head of the pharmacy is responsible for the activities of the branch pharmacy and pharmacy counter. </inglise>
<eesti>(3) Haiglaapteek varustab ravimite ja teiste meditsiiniotstarbeliste toodetega teda organiseerinud haiglat ning vajadusel ka teisi sama kohaliku omavalitsuse territooriumil asuvaid ravi- ja hoolekandeasutusi ning ei oma ravimite jaem&uuml;&uuml;gi&otilde;igust. </eesti>
<inglise>(3) A hospital pharmacy supplies the hospital it is founded by and, if necessary, other medical and social welfare institutions in the territory of the local government with medicinal products and other products for medical purposes, and does not have the right to engage in retail trade of medicinal products. </inglise>
<eesti>(4) Haruapteegile, apteegi m&uuml;&uuml;gipunktile ja haiglaapteegile esitatavad n&otilde;uded, nende asutamise ja sulgemise korra kehtestab sotsiaalminister. </eesti>
<inglise>(4) The requirements set for branch pharmacies, pharmacy counters and hospital pharmacies and the procedures for their foundation and termination shall be established by the Minister of Social Affairs. </inglise>
<eesti>(5) Apteegis v&otilde;ivad ravimeid valmistada ja elanikele v&auml;ljastada ainult farmaatsiaalase haridusega t&ouml;&ouml;tajad. </eesti>
<inglise>(5) Medicinal products may be prepared and dispensed to the public from pharmacies only by persons educated in pharmacy. </inglise>
<eesti>Veterinaarias kasutatavaid ravimeid v&otilde;ivad ostjatele v&auml;ljastada ka veterinaararsti haridusega t&ouml;&ouml;tajad. </eesti>
<inglise>Medicinal products for use in veterinary medicine may also be dispensed by persons educated in veterinary medicine. </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(6) Apteegi juhataja ametikohal v&otilde;ib t&ouml;&ouml;tada isik, kellel on Sotsiaalministeeriumi v&auml;ljaantud ravimite jaem&uuml;&uuml;gi tegevusluba. </eesti>
<inglise>(6) Only a person who holds an activity licence issued by the Ministry of Social Affairs for retail trade of medicinal products may work as the head of a pharmacy. </inglise>
<eesti>&Uuml;hel isikul on &otilde;igus omada &uuml;hte ravimite jaem&uuml;&uuml;gi tegevusluba. </eesti>
<inglise>A person has the right to hold one activity licence for retail trade of medicinal products. </inglise>
<eesti>Tegevusloa loovutamine v&otilde;i m&otilde;nel muul viisil edasiandmine ei ole lubatud. </eesti>
<inglise>Assignment of an activity licence or transfer in any other manner is not permitted. </inglise>
<eesti>(7) Ravimite jaem&uuml;&uuml;gi tegevusloa annab v&auml;lja Sotsiaalministeerium tegevuseks kindlal aadressil kohalikult omavalitsuselt tegutsemisloa saanud isikule, kellel on k&otilde;rgem farmaatsiaalane haridus v&otilde;i ainult veterinaarravimite puhul veterinaararsti haridus ning v&auml;hemalt viieaastane erialane staa&zcaron;. </eesti>
<inglise>(7) An activity licence for retail trade of medicinal products shall be issued by the Ministry of Social Affairs for activity at a specified address to a person who has obtained an operating licence from the local government, has completed higher education in pharmacy or, in the case of veterinary medicinal products only, higher education in veterinary medicine and has at least five years of professional experience. </inglise>
<eesti>Ravimiametil on &otilde;igus sotsiaalministri kehtestatud korras teha taotlejale ettekirjutusi apteegi paiknemise, t&ouml;&ouml;re&zcaron;iimi ja ravimite sortimendi osas. </eesti>
<inglise>The Agency of Medicines has the right to issue precepts pursuant to procedure established by the Minister of Social Affairs to an applicant regarding the location and operations of the pharmacy and the assortment of medicinal products. </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(8) Ravimite jaem&uuml;&uuml;gi tegevusluba t&uuml;histatakse, kui on muutunud tingimused, mille p&otilde;hjal tegevusluba v&auml;ljastati v&otilde;i kui tegevusloa saanu ei ole kuue kuu jooksul alustanud tegevust v&otilde;i kui tegevusloa saanud isik ei oma t&auml;ielikku kontrolli apteegi tegevuse &uuml;le. </eesti>
<inglise>(8) An activity licence for retail trade of medicinal products shall be revoked if the conditions which were the basis for issue of the activity licence change, the holder of the activity licence has not commenced activities within six months or the holder of the activity licence lacks full control over the activities of the pharmacy. </inglise>
<eesti>(9) Apteek v&otilde;ib p&otilde;hineda f&uuml;&uuml;silise isiku v&otilde;i era&otilde;igusliku juriidilise isiku, samuti riigi, kohaliku omavalitsus&uuml;ksuse v&otilde;i muu avalik-&otilde;igusliku juriidilise isiku omandil. </eesti>
<inglise>(9) A natural person, legal person in private law, the state, a local government or other legal person in public law may be the owner of a pharmacy. </inglise>
<eesti>(26.06.96 j&otilde;ust.26.07.96 - RT I 1996, 49, 954) </eesti>
<inglise>(26.06.96 entered into force 26.07.96 - RT I 1996, 49, 954) </inglise>
<eesti>(10) (Kehtetu - 26.06.96 j&otilde;ust.26.07.96 - RT I 1996, 49, 954) </eesti>
<inglise>(10) (Repealed - 26.06.96 entered into force 26.07.96 - RT I 1996, 49, 954) </inglise>
<eesti>(11) Apteegi juhataja vastutab, et apteegi tegevuses peetaks kinni ravimialastest &otilde;igusaktidest ning tagab Eesti Vabariigis registreeritud ravimite k&auml;ttesaadavuse. </eesti>
<inglise>(11) The head of a pharmacy is responsible for compliance with legislation governing medicinal products in the operation of the pharmacy and shall ensure the availability of medicinal products registered in the Republic of Estonia. </inglise>
<eesti>(12) Apteegi sulgemisest tuleb teatada kaks kuud varem kohalikule omavalitsusele ja Ravimiametile. </eesti>
<inglise>(12) The local government and the Agency of Medicines shall be notified of the termination of a pharmacy two months in advance. </inglise>
<eesti>Apteegi sulgemisel v&otilde;i omaniku vahetumisel v&otilde;ib apteegis olemasolevaid ravimeid realiseerida vaid ravimite hulgim&uuml;&uuml;gi v&otilde;i jaem&uuml;&uuml;gi tegevusluba omavatele ettev&otilde;tetele. </eesti>
<inglise>Upon termination or change of ownership of a pharmacy, the medicinal products existing in the pharmacy may only be sold to enterprises which hold an activity licence for wholesale or retail trade of medicinal products. </inglise>
<eesti>Suletava apteegi ravimivaru realiseerimist kontrollib Ravimiamet. </eesti>
<inglise>The sale of the stock of medicinal products of a pharmacy being terminated shall be inspected by the Agency of Medicines. </inglise>
<eesti>&sect; 11. </eesti>
<inglise>&sect; 11. </inglise>
<eesti>Ravimite registreerimine </eesti>
<inglise>Registration of medicinal products </inglise>
<eesti>(1) Ravimi registreerimiseks esitab ravimitootja taotluse Ravimiametile. </eesti>
<inglise>(1) In order to register a medicinal product, the manufacturer of the medicinal product shall submit an application to the Agency of Medicines. </inglise>
<eesti>(2) Ravimite registreerimise aluseks on ravimpreparaadi tootja taotlus koos t&auml;iendava dokumentatsiooniga, Ravimiameti poolt ettevalmistatud eksperdihinnangud ja teostatud ravimi keemilis-farmatseutiliste omaduste kontroll. </eesti>
<inglise>(2) Registration of a medicinal product shall be based on an application from the manufacturer of the medicinal product together with supporting documentation, expert assessments and the results of testing for the chemical and pharmaceutical characteristics of the medicinal product conducted by the Agency of Medicines. </inglise>
<eesti>(3) (Kehtetu - 30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(3) (Repealed - 30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>(4) Ravim registreeritakse 210 kalendrip&auml;eva jooksul, alates taotluse vastuv&otilde;tmise p&auml;evast, kui taotleja on t&otilde;estanud ravimi efektiivsuse ja ohutuse selle eesm&auml;rgip&auml;rase kasutamise korral ning ravimi kvaliteet vastab kehtestatud n&otilde;uetele. </eesti>
<inglise>(4) A medicinal product shall be registered within 210 days as of the date of receipt of the application, if the applicant has proved the efficacy and safety of the medicinal product upon use thereof for its intended purpose and the quality of the medicinal product meets the established requirements. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>(5) Ravimi registreerimisel v&auml;ljastab Ravimiamet taotluse esitajale ravimi m&uuml;&uuml;giloa, mille kehtivusaeg on kuni viis aastat, kehtestades vajadusel piirangud ravimiga kauplemisel ja selle tarvitamisel. </eesti>
<inglise>(5) Upon registration of a medicinal product, the Agency of Medicines shall issue a marketing authorisation for the medicinal product to the applicant, valid for up to five years, and, if necessary, shall establish restrictions on trade and use of the medicinal product. </inglise>
<eesti>(6) Ravimiamet v&otilde;ib sotsiaalministri kehtestatud korras ravimi registreerimisest p&otilde;hjendatud otsusega keelduda. </eesti>
<inglise>(6) Pursuant to procedure established by the Minister of Social Affairs, the Agency of Medicines may refuse to register a medicinal product by a reasoned decision. </inglise>
<eesti>(7) Ravimiamet v&otilde;ib n&otilde;uda tootjalt ravimi kohta t&auml;iendavat informatsiooni. </eesti>
<inglise>(7) The Agency of Medicines may require additional information from the manufacturer concerning a medicinal product. </inglise>
<eesti>Selle mitteesitamisel v&otilde;ib Ravimiamet keelduda ravimi registreerimisest v&otilde;i t&uuml;histada m&uuml;&uuml;giloa. </eesti>
<inglise>Upon failure to submit such information, the Agency of Medicines may refuse to register the medicinal product or revoke the marketing authorisation. </inglise>
<eesti>(8) Ravimpreparaadi v&otilde;i ravimisarnase aine koostist, pakendit v&otilde;i markeeringut v&otilde;ib Ravimiameti loal muuta ilma uue registreerimiseta tingimusel, et ravim ise v&otilde;i selle kasutamise n&auml;idustused ei ole oluliselt muutunud. </eesti>
<inglise>(8) With the permission of the Agency of Medicines, the composition, packaging or labelling of a proprietary medicinal product or semi-medicinal product may be altered without new registration on the condition that the medicinal product itself or its indications are not significantly changed. </inglise>
<eesti>(9) Ravimiamet v&otilde;ib sotsiaalministri kehtestatud korras t&uuml;histada v&otilde;i peatada ravimi registreerimise ja m&uuml;&uuml;giloa, kui ravimi registreerimise ja m&uuml;&uuml;giloa andmise tingimused on muutunud v&otilde;i t&auml;itmata v&otilde;i on eiratud ravimi turustamisele esitatud n&otilde;udmisi v&otilde;i ei ole tagatud ravimi k&auml;ttesaadavus. </eesti>
<inglise>(9) The Agency of Medicines may revoke or suspend the registration and marketing authorisation of a medicinal product pursuant to procedure established by the Minister of Social Affairs if the conditions for registration and issue of the marketing authorisation have changed or are not fulfilled, the requirements set for marketing the medicinal product are ignored or the availability of the medicinal product is not ensured. </inglise>
<eesti>(10) Ravimi registreerimise taotluse esitamisel tasub taotluse esitaja ekspertiisikulud sotsiaalministri kehtestatud korras ja riigil&otilde;ivu. </eesti>
<inglise>(10) Upon submission of an application for registration of a medicinal product, the applicant shall pay the costs of expertise pursuant to procedure established by the Minister of Social Affairs and the state fee. </inglise>
<eesti>(11) Ravimiamet teeb vajadusel otsuseid diagnostiliste ainete ja testide, radioaktiivsete, immunoloogiliste ja verepreparaatide, rasestumisvastaste ja kosmeetiliste vahendite registreerimise kohta. </eesti>
<inglise>(11) If necessary, the Agency of Medicines shall make decisions concerning the registration of diagnostic substances and tests, radioactive, immunologic and blood preparations, and contraceptive and cosmetic devices. </inglise>
<eesti>&sect; 12. </eesti>
<inglise>&sect; 12. </inglise>
<eesti>Ravimite s&auml;ilitamine </eesti>
<inglise>Storage of medicinal products </inglise>
<eesti>(1) Ravimeid turustades, transportides v&otilde;i s&auml;ilitades tuleb v&auml;listada nende sattumine k&otilde;rvaliste isikute k&auml;tte ning muutumine ravimi kasutajale v&otilde;i keskkonnale ohtlikuks. </eesti>
<inglise>(1) In marketing, transporting and storing medicinal products, it shall be ensured that such products do not fall into the hands of unauthorised persons or become dangerous to users of medicinal products or the environment. </inglise>
<eesti>(2) K&otilde;ik ravimid, mille k&otilde;lblikkusaeg on m&ouml;&ouml;das v&otilde;i mis on k&auml;ibelt k&otilde;rvaldatud teistel p&otilde;hjustel, tuleb muuta inimesele, loomale ja keskkonnale ohutult kahjutuks sotsiaalministri kehtestatud korras. </eesti>
<inglise>(2) All medicinal products the date of expiry of which has passed or which are removed from the market for other reasons shall be safely rendered harmless to humans, animals and the environment pursuant to procedure established by the Minister of Social Affairs. </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(3) Ravimite s&auml;ilitamise ja transportimise eeskirjad kehtestab sotsiaalminister. </eesti>
<inglise>(3) Rules for storage and transport of medicinal products shall be established by the Minister of Social Affairs. </inglise>
<eesti>&sect; 13. </eesti>
<inglise>&sect; 13. </inglise>
<eesti>Ravimi kliinilise uuringu m&otilde;iste </eesti>
<inglise>Definition of clinical trial of medicinal product </inglise>
<eesti>(1) Ravimi kliiniline uuring on ravimite kasutamine inimesel v&otilde;i veterinaarravimite kasutamine loomal andmete kogumiseks ravimi toime, k&otilde;rvaltoime, imendumise, jaotumise, muutumise, v&auml;ljutamise, efektiivsuse ja ohutuse kohta. </eesti>
<inglise>(1) A clinical trial of a medicinal product is the use of a medicinal product in humans or the use of a veterinary medicinal product on animals in order to collect information on the effect, side effects, absorption, distribution, metabolism, excretion, efficacy and safety of the medicinal product. </inglise>
<eesti>(2) Ravimi kliinilise uuringu alguseks loetakse teabe avalikustamist uuringu toimumise kohta v&otilde;imalikele uuringus osalejatele, veterinaarravimi kliinilise uuringu puhul looma omanikule v&otilde;i uuringuga seotud toimingute teostamist. </eesti>
<inglise>(2) The publication of information concerning a clinical trial to possible trial subjects, the owner of the animal in the case of a clinical trial of a veterinary medicinal product or the performance of procedures related to the trial is deemed to be the commencement of the clinical trial. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>&sect; 13 (1). </eesti>
<inglise>&sect; 13 (1). </inglise>
<eesti>Ravimi kliinilise uuringu n&otilde;uded </eesti>
<inglise>Requirements for clinical trials of medicinal products </inglise>
<eesti>(1) Kliiniliselt v&otilde;ib uurida ainult neid ravimeid, mis on toodetud k&auml;esoleva seaduse ja selle alusel kehtestatud &otilde;igusaktide n&otilde;uete kohaselt ja mille toimete ja k&otilde;rvaltoimete kohta on uuringut l&auml;biviival isikul piisavalt kaasajastatud teavet. </eesti>
<inglise>(1) Clinical trials may only be conducted with regard to medicinal products which are manufactured in compliance with the requirements of this Act and legislation established on the basis thereof and regarding which the person conducting the clinical trial has sufficient up-to-date information on its effects and side effects. </inglise>
<eesti>(2) Ravimi kliinilise uuringu planeerimine, l&auml;biviimine ja saadud tulemuste avaldamine peab olema koosk&otilde;las hea kliinilise tava kvaliteedin&otilde;uetega. </eesti>
<inglise>(2) The planning and conducting of a clinical trial of a medicinal product and the publication of the results thereof shall be in compliance with the quality requirements of good clinical practice. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>&sect; 13 (2). </eesti>
<inglise>&sect; 13 (2). </inglise>
<eesti>Ravimi kliinilise uuringu l&auml;biviijad ja nende &otilde;igused ning kohustused </eesti>
<inglise>Persons who conduct clinical trials of medicinal products and their rights and obligations </inglise>
<eesti>(1) Ravimi kliinilist uuringut v&otilde;ivad l&auml;bi viia arstid, hambaarstid ja veterinaararstid ainult oma erialal oma p&auml;devuse piires. </eesti>
<inglise>(1) Clinical trials of medicinal products may be conducted by doctors, dentists and veterinarians only in their respective areas of specialisation and within the limits of their competence. </inglise>
<eesti>(2) Ravimi kliinilise uuringu l&auml;biviimises v&otilde;ivad osaleda teised tervishoiuteenuse osutajad ja ravimitootjad v&otilde;i nende esindajad. </eesti>
<inglise>(2) Other providers of health services and manufacturers of medicinal products or representatives thereof may participate in conducting a clinical trial of a medicinal product. </inglise>
<eesti>(3) Kui ravimi kliinilise uuringu l&auml;biviimises osalevad mitu arsti, hambaarsti v&otilde;i veterinaararsti v&otilde;i osaleb uuringus teisi tervishoiuteenuse osutajaid v&otilde;i ravimitootjaid v&otilde;i nende esindajaid, m&auml;&auml;ratakse nende omavahelised &otilde;igused ja kohustused kindlaks nendevahelises lepingus. </eesti>
<inglise>(3) If several doctors, dentists or veterinarians participate in conducting a clinical trial of a medicinal product or other providers of health services and manufacturers of medicinal products or representatives thereof participate in a trial, their mutual rights and obligations shall be determined in an agreement entered into between them. </inglise>
<eesti>(4) Kui ravimi kliinilise uuringu algatamises, korraldamises v&otilde;i l&auml;biviimises osaleb ravimitootja v&otilde;i tema esindaja, tagab ta uuringut l&auml;biviivale arstile, hambaarstile v&otilde;i veterinaararstile t&otilde;ese ja ammendava teabe uuritava ravimi kohta. </eesti>
<inglise>(4) If the manufacturer of a medicinal product or a representative of the manufacturer participates in the commencement, organisation or conduct of a clinical trial of a medicinal product, such person shall provide the doctor, dentist or veterinarian conducting the trial with true and exhaustive information concerning the medicinal product being investigated. </inglise>
<eesti>(5) Uuringut l&auml;biviiv arst, hambaarst, veterinaararst ja uuringus osalev tervishoiuteenuse osutaja annavad oma p&auml;devuse piires uuringus osalejale vajalikku abi. </eesti>
<inglise>(5) A doctor, dentist or veterinarian conducting a trial and a provider of health services participating in a trial shall provide necessary assistance to a trial subject within the limits of his or her competence. </inglise>
<eesti>(6) Vajadusel kindlustab uuringut l&auml;biviiv arst v&otilde;i hambaarst uuringus osalejale teiste tervishoiuteenuste osutajate p&auml;deva abi k&auml;ttesaadavuse. </eesti>
<inglise>(6) A doctor or dentist conducting a trial shall ensure the availability of competent assistance of other health service providers to the trial subject if necessary. </inglise>
<eesti>Veterinaarravimi kliinilise uuringu korral kindlustab veterinaararst uuringus osalejale vajadusel teiste veterinaararstide p&auml;deva abi k&auml;ttesaadavuse. </eesti>
<inglise>In the case of a clinical trial of a veterinary medicinal product, the veterinarian shall ensure the availability of competent assistance of other veterinarians to the trial subject. </inglise>
<eesti>(7) Uuringut l&auml;biviiv arst v&otilde;i hambaarst on kohustatud uuringus osalejat ja k&auml;esolevas seaduses etten&auml;htud juhtudel uuringus osaleja seaduslikku esindajat ning veterinaararst uuringusse kaasatud looma omanikku teavitama ravimi kliinilise uuringuga seotud asjaoludest, sealhulgas v&otilde;imalikest ohtudest ning uuringuga seotud tervisekahjustuse h&uuml;vitamise viisist ja m&auml;&auml;rast. </eesti>
<inglise>(7) A doctor or dentist conducting a trial is required to inform the trial subject and, in the cases prescribed in this Act, the legal representative of the trial subject and a veterinarian is required to inform the owner of an animal involved in the trial of facts related to the clinical trial of the medicinal product, including possible hazards and the manner and rate of compensation for any health damage sustained in connection with the trial. </inglise>
<eesti>(8) Uuringut l&auml;biviiv arst, hambaarst v&otilde;i veterinaararst on kohustatud j&auml;rgima ravimi kliinilise uuringu l&auml;biviimise korda. </eesti>
<inglise>(8) A doctor, dentist or veterinarian conducting a trial is required to observe the procedure for conducting clinical trials of medicinal products. </inglise>
<eesti>(9) Ravimi kliinilise uuringu l&auml;biviimise korra kehtestab sotsiaalminister m&auml;&auml;rusega. </eesti>
<inglise>(9) The procedure for conducting clinical trials of medicinal products shall be established by a regulation of the Minister of Social Affairs. </inglise>
<eesti>(10) Uuringut l&auml;biviiv arst, hambaarst v&otilde;i veterinaararst ning uuringu l&auml;biviimises osalev ravimitootja v&otilde;i tema esindaja teatavad kirjalikult sotsiaalministri kehtestatud korras Ravimiametile, veterinaarravimi uuringu puhul ka Veterinaar- ja Toiduametile uuringu k&auml;igus ilmnenud t&otilde;sistest k&otilde;rvaln&auml;htudest ning muudatustest uuringuplaanis. </eesti>
<inglise>(10) A doctor, dentist or veterinarian conducting a trial and a manufacturer of medicinal products or a representative thereof participating in the conduct of a trial shall notify, pursuant to the procedure established by the Minister of Social Affairs, the Agency of Medicines and, in the case of a trial of a veterinary medicinal product, the Veterinary and Food Board in writing of any serious side-effects which appear in the course of the trial and amendments to the clinical trial protocol. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>&sect; 13 (3). </eesti>
<inglise>&sect; 13 (3). </inglise>
<eesti>N&otilde;usolek ravimi kliinilises uuringus osalemiseks </eesti>
<inglise>Consent to participate in clinical trial of medicinal product </inglise>
<eesti>(1) Ravimi kliiniliseks uuringuks on n&otilde;utav uuringus osaleja n&otilde;usolek. </eesti>
<inglise>(1) Consent of the trial subject is required for a clinical trial of a medicinal product. </inglise>
<eesti>N&otilde;usolek antakse p&auml;rast k&otilde;igist ravimi kliinilise uuringu asjaoludest teavitamist ja n&otilde;usolek dokumenteeritakse. </eesti>
<inglise>Consent is given after having been informed of all facts relating to the clinical trial of a medicinal product and consent shall be documented. </inglise>
<eesti>N&otilde;usoleku v&otilde;ib igal ajal tagasi v&otilde;tta. </eesti>
<inglise>Consent may be withdrawn at any time. </inglise>
<eesti>(2) Teov&otilde;imetu v&otilde;i piiratud teov&otilde;imega isiku ravimi kliinilises uuringus osalemiseks annab n&otilde;usoleku tema seaduslik esindaja, 7-18-aastase alaealise uuringus osalemiseks on vajalik ka alaealise enda n&otilde;usolek. </eesti>
<inglise>(2) Consent to the participation of a person without active legal capacity or with restricted active legal capacity in a clinical trial of a medicinal product is given by the legal representative of such person, for a minor who is 7-18 years old to participate in a trial, the consent of the minor is necessary. </inglise>
<eesti>(3) Looma kaasamiseks veterinaarravimi kliinilisse uuringusse annab n&otilde;usoleku looma omanik. </eesti>
<inglise>(3) In order to involve an animal in a clinical trial of a veterinary medicinal product, the owner of the animal shall give his or her consent. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>&sect; 13 (4). </eesti>
<inglise>&sect; 13 (4). </inglise>
<eesti>Ravimi kliinilise uuringu l&auml;biviimise koosk&otilde;lastamine </eesti>
<inglise>Approval of conduct of clinical trials of medicinal products </inglise>
<eesti>(1) Ravimi kliinilist uuringut ei v&otilde;i alustada enne koosk&otilde;lastuse saamist kliiniliste uuringute meditsiinieetika komiteelt. </eesti>
<inglise>(1) A clinical trial of a medicinal product shall not commence without the approval of the medical ethics committee for clinical trials. </inglise>
<eesti>(2) Kliiniliste uuringute meditsiinieetika komitee annab ravimi kliinilise uuringu l&auml;biviimisele eetilise hinnangu. </eesti>
<inglise>(2) The medical ethics committee for clinical trials shall assess the ethics of conducting a clinical trial of a medicinal product. </inglise>
<eesti>(3) Sotsiaalminister kehtestab n&otilde;uded kliiniliste uuringute meditsiinieetika komitee koosseisule, komitee t&ouml;&ouml;korra, kliinilise uuringu hindamise tasu m&auml;&auml;ra ja koosk&otilde;lastuse saamiseks esitatavate andmete loetelu m&auml;&auml;rusega. </eesti>
<inglise>(3) The Minister of Social Affairs shall establish, by a regulation, the requirements for membership of the medical ethics committee for clinical trials, the rules of procedure of the committee, the rate of the fee for the evaluation of clinical trials and the list of information to be submitted in order to obtain approval. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>&sect; 13 (5). </eesti>
<inglise>&sect; 13 (5). </inglise>
<eesti>Taotluse esitamine ravimi kliinilise uuringu l&auml;biviimiseks </eesti>
<inglise>Submission of application to conduct clinical trial of medicinal product </inglise>
<eesti>(1) Ravimi kliinilise uuringu l&auml;biviimiseks esitab arst, hambaarst v&otilde;i veterinaararst kirjaliku taotluse ning k&auml;esoleva paragrahvi l&otilde;ikes 3 nimetatud andmed ja dokumendid Ravimiametile v&auml;hemalt kaks kuud enne planeeritud uuringu algust. </eesti>
<inglise>(1) In order to conduct a clinical trial of a medicinal product, a doctor, dentist or veterinarian shall submit a written application and the information and documents specified in subsection (3) of this section to the Agency of Medicines not later than two months prior to the commencement of the planned trial. </inglise>
<eesti>(2) Ravimi kliinilise uuringu l&auml;biviimise taotluse vormin&otilde;uded kehtestab sotsiaalminister m&auml;&auml;rusega. </eesti>
<inglise>(2) Formal requirements for applications to conduct clinical trials of medicinal products shall be established by a regulation of the Minister of Social Affairs. </inglise>
<eesti>(3) Ravimi kliinilise uuringu l&auml;biviimise taotlusele lisatakse j&auml;rgmised andmed ja dokumendid: </eesti>
<inglise>(3) The following information and documents shall be attached to an application to conduct a clinical trial of a medicinal product: </inglise>
<eesti>1) uuringuplaan; </eesti>
<inglise>1) a trial protocol; </inglise>
<eesti>2) andmed uuritava ravimi farmatseutilis-keemiliste ja farmakoloogilistoksikoloogiliste omaduste kohta; </eesti>
<inglise>2) information concerning the pharmaceutical and chemical characteristics and pharmaco-toxicological characteristics of the medicinal product being investigated; </inglise>
<eesti>3) seni l&auml;biviidud ravimi kliiniliste uuringute tulemused; </eesti>
<inglise>3) the results of previously conducted clinical trials of the medicinal product; </inglise>
<eesti>4) kliiniliste uuringute meditsiinieetika komitee koosk&otilde;lastus; </eesti>
<inglise>4) the approval of the medical ethics committee for clinical trials; </inglise>
<eesti>5) kindlustussertifikaadi koopia. </eesti>
<inglise>5) a copy of the insurance certificate. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>&sect; 13 (6). </eesti>
<inglise>&sect; 13 (6). </inglise>
<eesti>Ravimi kliiniliseks uuringuks n&otilde;usoleku andmine </eesti>
<inglise>Grant of consent to clinical trial of medicinal product </inglise>
<eesti>(1) N&otilde;usoleku ravimi kliinilise uuringu l&auml;biviimiseks annab Ravimiameti peadirektor. </eesti>
<inglise>(1) Consent to conduct a clinical trial of a medicinal product shall be granted by the Director General of the Agency of Medicines. </inglise>
<eesti>(2) N&otilde;usolek veterinaarravimi kliinilise uuringu l&auml;biviimiseks koosk&otilde;lastatakse Veterinaar- ja Toiduametiga. </eesti>
<inglise>(2) Consent to conduct a clinical trial of a veterinary medicinal product shall be approved by the Veterinary and Food Board. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>&sect; 13 (7). </eesti>
<inglise>&sect; 13 (7). </inglise>
<eesti>N&otilde;usoleku andmisest keeldumine </eesti>
<inglise>Refusal to grant consent </inglise>
<eesti>(1) Ravimiamet v&otilde;ib keelduda n&otilde;usoleku andmisest ravimi kliinilise uuringu l&auml;biviimiseks, kui: </eesti>
<inglise>(1) The Agency of Medicines may refuse to grant consent to the conduct of a clinical trial of a medicinal product if: </inglise>
<eesti>1) taotleja ei t&auml;ida ravimi kliinilise uuringu n&otilde;udeid; </eesti>
<inglise>1) the applicant does not comply with the requirements for clinical trials of medicinal products; </inglise>
<eesti>2) taotleja on esitanud puuduliku v&otilde;i v&auml;&auml;ra teabe; </eesti>
<inglise>2) the applicant submitted insufficient or false information; </inglise>
<eesti>3) uuringuplaan on ebaotstarbekas; </eesti>
<inglise>3) the trial protocol is unreasonable; </inglise>
<eesti>4) uuringul puudub teaduslik v&auml;&auml;rtus; </eesti>
<inglise>4) the trial is of no scientific value; </inglise>
<eesti>5) risk uuringus osaleja elule ja tervisele on suur. </eesti>
<inglise>5) the risk to the life and health of trial subjects is high. </inglise>
<eesti>(2) Ravimiamet teatab taotlejale n&otilde;usoleku andmisest keeldumisest kirjalikult 60 t&ouml;&ouml;p&auml;eva jooksul taotluse vastuv&otilde;tmisest alates. </eesti>
<inglise>(2) The Agency of Medicines shall notify the applicant of a refusal to grant consent in writing within sixty working days as of the receipt of the application. </inglise>
<eesti>Kui Ravimiamet ei ole nimetatud t&auml;htaja jooksul taotlejale n&otilde;usoleku andmisest keeldumisest teatanud ega n&otilde;udnud lisaandmeid, loetakse n&otilde;usolek antuks. </eesti>
<inglise>If the Agency of Medicines has not notified the applicant of the refusal to grant consent or requested additional information within the specified term, consent is deemed to be granted. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>&sect; 13 (8). </eesti>
<inglise>&sect; 13 (8). </inglise>
<eesti>Ravimi kliinilise uuringu peatamine </eesti>
<inglise>Suspension of clinical trial of medicinal product </inglise>
<eesti>(1) Ravimiamet v&otilde;i Veterinaar- ja Toiduamet peatavad alanud ravimi kliinilise uuringu, kui uuringu k&auml;igus on ilmnenud k&auml;esoleva seaduse &sect; 13 (7) l&otilde;ikes 1 nimetatud asjaolud. </eesti>
<inglise>(1) The Agency of Medicines or the Veterinary and Food Board shall suspend a commenced clinical trial of a medicinal product if facts specified in subsection 13 (7) (1) of this Act become evident in the course of the trial. </inglise>
<eesti>(2) Uuringu l&auml;biviija on kohustatud uuringu peatama kohe p&auml;rast Ravimiameti v&otilde;i Veterinaar- ja Toiduameti vastava otsuse k&auml;ttesaamist. </eesti>
<inglise>(2) The person conducting the clinical trial is required to suspend the trial immediately after the receipt of the corresponding decision of the Agency of Medicines or the Veterinary and Food Board. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>&sect; 13 (9). </eesti>
<inglise>&sect; 13 (9). </inglise>
<eesti>Ravimi kliinilise uuringu l&auml;biviijate vastutus </eesti>
<inglise>Liability of persons conducting clinical trials of medicinal products </inglise>
<eesti>(1) Ravimi kliinilist uuringut l&auml;biviiv arst, hambaarst v&otilde;i veterinaararst vastutab oma kohustuste rikkumise eest &uuml;ksnes temast tulenevate asjaolude esinemise korral. </eesti>
<inglise>(1) A doctor, dentist or veterinarian conducting a clinical trial of a medicinal product shall be liable for a violation of his or her obligations only if circumstances depending on the doctor, dentist or veterinarian occur. </inglise>
<eesti>(2) Kui ravimi kliinilist uuringut l&auml;biviiv arst, hambaarst v&otilde;i veterinaararst tegutseb ravimi kliinilise uuringu l&auml;biviimisel kolmanda isikuga s&otilde;lmitud t&ouml;&ouml;- v&otilde;i muu lepingu alusel, vastutab kolmas isik solidaarselt arsti, hambaarsti v&otilde;i veterinaararstiga. </eesti>
<inglise>(2) If a doctor, dentist or veterinarian who conducts a clinical trial of a medicinal product is acting upon conducting the clinical trial of the medicinal product on the basis of an employment contract or another contract entered into with a third person, the third person shall be solidarily liable together with the doctor, dentist or veterinarian. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>&sect; 13 (10). </eesti>
<inglise>&sect; 13 (10). </inglise>
<eesti>J&auml;relevalve ravimi kliinilise uuringu &uuml;le </eesti>
<inglise>Supervision over clinical trials of medicinal products </inglise>
<eesti>(1) Ravimiametil on &otilde;igus p&auml;rast etteteatamist tutvuda ravimi kliinilise uuringu l&auml;biviimisega, kontrollida kinnipidamist uuringuplaanist ja kliiniliste uuringute l&auml;biviimise ning k&otilde;rvaln&auml;htudest teatamise korrast. </eesti>
<inglise>(1) The Agency of Medicines has the right upon advance notice to inspect the conduct of a clinical trial of a medicinal product and compliance with the trial protocol and the procedure for the conduct of clinical trials and for notification of side-effects. </inglise>
<eesti>(2) Ravimiametil on &otilde;igus tutvuda kliiniliste uuringute meditsiinieetika komitee t&ouml;&ouml;ga ning kontrollida kinnipidamist komitee t&ouml;&ouml;korrast. </eesti>
<inglise>(2) The Agency of Medicines has the right to inspect the work of the medical ethics committee for clinical trials and compliance with the rules of procedure of the committee. </inglise>
<eesti>(3) Ravimiametil on &otilde;igus saada ravimi kliinilise uuringu l&auml;biviijatelt, uuringu l&auml;biviimises osalevatelt tervishoiuteenuse osutajatelt ja ravimitootjatelt v&otilde;i nende esindajatelt ning meditsiinieetika komiteedelt teavet ravimi kliinilise uuringu ja selle l&auml;biviimise kohta. </eesti>
<inglise>(3) The Agency of Medicines is entitled to receive information concerning a clinical trial of a medicinal product and the conduct thereof from persons conducting the clinical trial of the medicinal product and providers of health services and manufacturers of medicinal products or representatives thereof participating in the conduct of the trial. </inglise>
<eesti>(30.06.2001 j&otilde;ust.01.07.2001 - RT I 2001, 53, 308) </eesti>
<inglise>(30.06.2001 entered into force 01.07.2001 - RT I 2001, 53, 308) </inglise>
<eesti>4. peat&uuml;kk </eesti>
<inglise>Chapter 4 </inglise>
<eesti>Kontroll ja vastutus </eesti>
<inglise>Control and Liability </inglise>
<eesti>&sect; 14. </eesti>
<inglise>&sect; 14. </inglise>
<eesti>Kontroll </eesti>
<inglise>Control </inglise>
<eesti>(1) Sotsiaalministeerium, Ravimiamet ning Veterinaar- ja Toiduamet kontrollivad vastavalt oma p&auml;devusele k&auml;esolevast seadusest ja selle alusel v&auml;lja antud &otilde;igusaktidest kinnipidamist. </eesti>
<inglise>(1) The Ministry of Social Affairs, the Agency of Medicines and the Veterinary and Food Board shall monitor compliance with this Act and legislation issued on the basis thereof, pursuant to their competence. </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(2) Ravimiameti t&ouml;&ouml;tajatel on &otilde;igus kontrollida ettev&otilde;tteid, kus toodetakse, s&auml;ilitatakse, turustatakse, kasutatakse v&otilde;i uuritakse ravimeid, samuti on neil &otilde;igus v&otilde;tta tasuta proove kontrollanal&uuml;&uuml;siks ning teostada ametikohustustega seotud uurimisi. </eesti>
<inglise>(2) Employees of the Agency of Medicines have the right to inspect enterprises which manufacture, store, market, use or investigate medicinal products, to take samples free of charge for control analysis and to perform investigations within the scope of their official duties. </inglise>
<eesti>(2 (1)) Veterinaar- ja Toiduameti ametnikud teostavad j&auml;relevalvet veterinaararstide ja loomseid saadusi tootvate loomapidajate poolse ravimite ja ravims&ouml;&ouml;tade kasutamise &uuml;le. </eesti>
<inglise>(2 (1)) Officials of the Veterinary and Food Board shall exercise supervision over the use of medicinal products and medicated feedingstuffs by veterinarians and breeders producing animal products. </inglise>
<eesti>(16.06.1999 j&otilde;ust.01.01.2000 - RT I 1999, 58, 608) </eesti>
<inglise>(16.06.1999 entered into force 01.01.2000 - RT I 1999, 58, 608) </inglise>
<eesti>(3) Kontrollitava ettev&otilde;tte juht on kohustatud andma kontrollijale vajalikku informatsiooni. </eesti>
<inglise>(3) The head of an enterprise under inspection is required to provide an inspector with necessary information. </inglise>
<eesti>(4) Kontrollides ettev&otilde;tteid, kus toodetakse ravimeid v&otilde;i tegeldakse nendega mingil muul viisil, peab kontrollimise k&auml;igus kindlaks tegema, kas ettev&otilde;tte tegevus toimub tingimustes, mis ei ohusta toodete kvaliteeti, ning kas ettev&otilde;tte v&otilde;i apteegi juhataja reaalselt kontrollib kogu tegevust. </eesti>
<inglise>(4) In the course of the inspection of an enterprise which manufactures or in any other manner deals with medicinal products, it shall be ascertained whether the enterprise is operating under conditions which do not jeopardise product quality and whether the head of the enterprise or pharmacy has actual control over all activities. </inglise>
<eesti>&sect; 15. </eesti>
<inglise>&sect; 15. </inglise>
<eesti>Vastutus k&auml;esoleva seaduse rikkumise eest </eesti>
<inglise>Liability for violation of this Act </inglise>
<eesti>(1) K&auml;esoleva seaduse rikkumises s&uuml;&uuml;diolevad isikud v&otilde;etakse distsiplinaar-, haldus- v&otilde;i kriminaalvastutusele seadusega etten&auml;htud korras. </eesti>
<inglise>(1) Persons guilty of a violation of this Act shall be held disciplinarily, administratively or criminally liable pursuant to procedure prescribed by law. </inglise>
<eesti>(2) K&otilde;ik isikud, kes on enda v&otilde;i kolmanda isiku huvides &auml;ra kasutanud informatsiooni, mida nad oma ametikohustuste t&otilde;ttu on teada saanud ravimitega tegeleva ettev&otilde;tte v&otilde;i apteegi &auml;ri- v&otilde;i ametisaladustest, peavad h&uuml;vitama tekitatud kahju seadusega etten&auml;htud korras. </eesti>
<inglise>(2) Everyone who uses information obtained due to their official duties concerning the business or professional secrets of an enterprise dealing with medicinal products or a pharmacy in the interests of themselves or a third person shall compensate for any damage caused, pursuant to procedure provided by law. </inglise>
<eesti>(3) K&auml;esoleva seaduse ja selle alusel antud &otilde;igusaktide rikkumise korral v&otilde;ib sotsiaalminister Ravimiameti p&otilde;hjendatud ettepanekul peatada ravimite tootmise, hulgi- v&otilde;i jaem&uuml;&uuml;gi tegevusloa kuni kolmeks kuuks. </eesti>
<inglise>(3) Upon violation of this Act or legislation based on this Act, the Minister of Social Affairs may on a reasoned proposal of the Agency of Medicines suspend an activity licence for the manufacture, wholesale or retail trade of medicinal products for up to three months. </inglise>
<eesti>(4) K&auml;esoleva seaduse ja selle alusel antud &otilde;igusaktide rikkumise korral v&otilde;ib sotsiaalminister Ravimiameti p&otilde;hjendatud ettepanekul t&uuml;histada ravimite tootmise, hulgi- v&otilde;i jaem&uuml;&uuml;gi tegevusloa. </eesti>
<inglise>(4) Upon violation of this Act or legislation based on this Act, the Minister of Social Affairs may on a reasoned proposal of the Agency of Medicines revoke an activity licence for the manufacture, wholesale or retail trade of medicinal products. </inglise>
<eesti>Uue tegevusloa taotluse v&otilde;ib esitada kahe aasta m&ouml;&ouml;dumisel. </eesti>
<inglise>An application for a new activity licence may be submitted after two years. </inglise>
<eesti>5. peat&uuml;kk </eesti>
<inglise>Chapter 5 </inglise>
<eesti>Eris&auml;tted </eesti>
<inglise>Special Provisions </inglise>
<eesti>&sect; 16. </eesti>
<inglise>&sect; 16. </inglise>
<eesti>Ravimi reklaam </eesti>
<inglise>Advertising of medicinal products </inglise>
<eesti>(1) Ravimi reklaamiks k&auml;esoleva seaduse t&auml;henduses loetakse ravimi v&auml;ljakirjutamise &otilde;igust omavale isikule suunatud reklaami. </eesti>
<inglise>(1) For the purposes of this Act, advertising directed at persons who are qualified to prescribe medicinal products is considered advertising of medicinal product. </inglise>
<eesti>(2) N&otilde;uded ja piirangud ravimi reklaamile, mis on suunatud &uuml;ldsusele, s&auml;testab reklaamiseadus (RT I 1997, 52, 835; 1999, 27, 388). </eesti>
<inglise>(2) Requirements for and restrictions on advertising of medicinal products directed to the public are provided for in the Advertising Act (RT I 1997, 52, 835; 1999, 27, 388). </inglise>
<eesti>(3) Reklaamida v&otilde;ib ainult Eestis registreeritud ravimit. </eesti>
<inglise>(3) Only medicinal products registered in Estonia may be advertised. </inglise>
<eesti>Ravimit v&otilde;ib reklaamida ainult ravimitootja sotsiaalministri kehtestatud korras. </eesti>
<inglise>A medicinal product may only be advertised by the manufacturer of the medicinal product pursuant to procedure established by the Minister of Social Affairs. </inglise>
<eesti>Ravimi n&auml;idiste andmist loetakse ravimi reklaamiks. </eesti>
<inglise>Offering samples of a medicinal product is considered advertising the medicinal product. </inglise>
<eesti>(4) Ravimi reklaamis esitatava informatsiooni &otilde;igsuse eest vastutab ravimitootja. </eesti>
<inglise>(4) Manufacturer of a medicinal product is liable for the correctness of information provided in advertising of medicinal products. </inglise>
<eesti>Kui ravimi reklaam sisaldab ravimi toime v&otilde;i teiste omaduste kohta valet, ohtlikult liialdatud v&otilde;i eksitavat informatsiooni, mis on vastuolus registreerimisel esitatuga, v&otilde;ib Ravimiamet t&uuml;histada vastava ravimpreparaadi m&uuml;&uuml;giloa. </eesti>
<inglise>If advertising of a medicinal product contains false, harmfully exaggerated or misleading information concerning the effect or other characteristics of the medicinal product which contradicts the information submitted upon registration, the Agency of Medicines may revoke the marketing authorisation of the corresponding proprietary medicinal product. </inglise>
<eesti>(5) Ravimi reklaam peab p&otilde;hinema ravimi omaduste kokkuv&otilde;ttel. </eesti>
<inglise>(5) Advertising of a medicinal product shall be based on the summary of product characteristics. </inglise>
<eesti>Ravimi omaduste kokkuv&otilde;te kinnitatakse ravimpreparaadi registreerimisel sotsiaalministri kehtestatud korras. </eesti>
<inglise>The summary of product characteristics shall be approved at the time of registration of a proprietary medicinal product pursuant to procedure established by the Minister of Social Affairs. </inglise>
<eesti>Ravimi omaduste kokkuv&otilde;tte koostamise ja kaasajastamise eest vastutab ravimitootja. </eesti>
<inglise>The manufacturer of a medicinal product is liable for preparing and updating the summary of product characteristics. </inglise>
<eesti>(6) Ravimi reklaam peab soodustama ravimi ratsionaalset kasutamist, esitades informatsiooni objektiivselt ja liialdusteta. </eesti>
<inglise>(6) Advertising of a medicinal product shall facilitate rational use of the medicinal product by presenting information in an objective and unexaggerated way. </inglise>
<eesti>(26.03.98 j&otilde;ust.03.05.98 - RT I 1998, 36/37, 554) </eesti>
<inglise>(26.03.98 entered into force 03.05.98 - RT I 1998, 36/37, 554) </inglise>
<eesti>6. peat&uuml;kk </eesti>
<inglise>Chapter 6 </inglise>
<eesti>Rakenduss&auml;tted </eesti>
<inglise>Implementing Provisions </inglise>
<eesti>&sect; 17. </eesti>
<inglise>&sect; 17. </inglise>
<eesti>Muudatused varasemates &otilde;igusaktides </eesti>
<inglise>Amendments to earlier legislation </inglise>
<eesti>(1) Kriminaalkoodeksis (RT 1992, 20, 228; 1999, 38, 485; 57, 595) tehakse j&auml;rgmised muudatused: </eesti>
<inglise>(1) The Criminal Code (RT 1992, 20, 228; 1999, 38, 485; 57, 595) is amended as follows: </inglise>
<eesti>1) paragrahvi 76 l&otilde;ikes 2 asendatakse s&otilde;nad "ps&uuml;hhotroopse, tugevatoimelise v&otilde;i m&uuml;rkaine" s&otilde;nadega "ps&uuml;hhotroopse aine, mittenarkootilise ravimi v&otilde;i m&uuml;rkaine"; </eesti>
<inglise>1) in subsection 76 (2), the words "a psychotropic, strong or toxic substance" are substituted by the words "a psychotropic substance, non-narcotic medicinal product or toxic substance"; </inglise>
<eesti>2) paragrahvis 210 asendatakse s&otilde;na "tugevatoimelise" s&otilde;nadega "mittenarkootilise ravimi" ja j&auml;etakse tekstist v&auml;lja s&otilde;nad "narkootiline v&otilde;i". </eesti>
<inglise>2) in &sect; 210, the word "strong" is substituted by the words "non-narcotic medicinal product", and the words "narcotic or" are repealed. </inglise>
<eesti>(2) Haldus&otilde;iguserikkumiste seadustikus (RT 1992, 29, 396; RT I 1999, 41, 496; 50, 548; 58, 608; 60, 616; 87, 792; 92, 825; 95, 843; 2000, 10, 58; 25, 141; 28, 167; 29, 169; 40, 247; 45, 279; 49, 301; 305; 51, 321; 54, 346; 348; 351; 55, 361; 58, 376; 84, 533; 86, 544; 548; 89, 578; 95, 609; 613; 2001, 3, 5; 9, 41; 17, 76; 18, 87; 21, 115; 116; 31, 174; 42, 236; 52, 303; 53, 312; 313; 314; 56, 333; 335; 339; 58, 356; 65, 378) tehakse j&auml;rgmised muudatused ja t&auml;iendused: </eesti>
<inglise>(2) The Code of Administrative Offences (RT 1992, 29, 396; RT I 1999, 41, 496; 50, 548; 58, 608; 60, 616; 87, 792; 92, 825; 95, 843; 2000, 10, 58; 25, 141; 28, 167; 29, 169; 40, 247; 45, 279; 49, 301; 305; 51, 321; 54, 346; 348; 351; 55, 361; 58, 376; 84, 533; 86, 544; 548; 89, 578; 95, 609; 613; 2001, 3, 5; 9, 41; 17, 76; 18, 87; 21, 115; 116; 31, 174; 42, 236; 52, 303; 53, 312; 313; 314; 56, 333; 335; 339; 58, 356; 65, 378) is amended as follows: </inglise>
<eesti>1) paragrahvi 38 l&otilde;ikes 4 asendatakse s&otilde;nad "riiklikku tegevuslitsentsi" s&otilde;naga "tegevusluba"; </eesti>
<inglise>1) in subsection 38 (4), the words "state activity licence" are substituted by the words "activity licence"; </inglise>
<eesti>2) paragrahvi 38 t&auml;iendatakse 5. l&otilde;ikega j&auml;rgmises s&otilde;nastuses: </eesti>
<inglise>2) subsection (5) is added to &sect; 38 worded as follows: </inglise>
<eesti>"(5) Tegevusluba omava isiku poolt riiklikult registreerimata ravimi hankimise, valmistamise, m&uuml;&uuml;mise, levitamise v&otilde;i reklaamimise, samuti ravimite tootmis-, impordi-, ekspordi-, ostu- m&uuml;&uuml;gi- ja reklaamieeskirjade rikkumise eest - m&auml;&auml;ratakse rahatrahv kuni saja p&auml;evapalga ulatuses." </eesti>
<inglise>"(5) For the procurement, production, sale, distribution or advertising of medicinal products which are not registered by the state by a person who holds an activity license or for violation of rules for the manufacture, import, export, purchase, sale and advertising of medicinal products, a fine up to the extent of one hundred days' wages shall be imposed." </inglise>
<eesti>; </eesti>
<inglise>; </inglise>
<eesti>3) paragrahvi 137 l&otilde;ike 1 ja 2 loetelu t&auml;iendatakse s&otilde;nadega "38 lg. 4"; </eesti>
<inglise>3) the words "subsection 38 (4)" are added to the lists in subsections 137 (1) and (2); </inglise>
<eesti>4) paragrahvi 205 l&otilde;iget 1 muudetakse p&auml;rast s&otilde;nu "37 lg. 2" ja s&otilde;nastatakse j&auml;rgmiselt: </eesti>
<inglise>4) subsection 205 (1) is amended after the words "subsection 37(2)" and is worded as follows: </inglise>
<eesti>"38 lg. 1, 2, 3 ja 5, 53 lg. 1, 58, 58'1, 60, 132 (ravimite osas), 134 (ravimite osas), 135, 169 p. 1 ja 2 (ravimite osas) ning 179 loetletud haldus&otilde;iguserikkumiste asju"; 5) paragrahvi 205 l&otilde;ike 2 punkt 3 muudetakse ja s&otilde;nastatakse j&auml;rgmiselt: </eesti>
<inglise>"administrative offences set out in subsections 38 (1), (2), (3) and (5), subsection 53 (1), &sect;&sect; 58, 581, 60, 132 (with regard to medicinal products), &sect; 134 (with regard to medicinal products), &sect; 135, clauses 169 1) and 2) (with regard to medicinal products) and &sect; 179"; 5) clause 205 (2) 3) is amended and worded as follows: </inglise>
<eesti>"3) Ravimiameti peadirektoril ja tema aset&auml;itjal k&auml;esoleva seadustiku paragrahvide 38 lg. 3 ja 5, 132 (ravimite osas), 134 (ravimite osas), 135 (ravimite osas) ning 169 p. 1 ja 2 (ravimite osas) j&auml;rgi." </eesti>
<inglise>"3) the Director General and Deputy Director General of the Agency of Medicines under subsections 38 (3) and (5), &sect; 132 (with regard to medicinal products), &sect; 134 (with regard to medicinal products), &sect; 135 (with regard to medicinal products) and clauses 169 1) and 2) (with regard to medicinal products)." </inglise>
<eesti>; </eesti>
<inglise>; </inglise>
<eesti>6) paragrahvi 205 l&otilde;ike 3 loetelus asendatakse s&otilde;nad "135 lg. 1 ja 2" arvuga "135". </eesti>
<inglise>6) the words "subsections 135 (1) and (2)" are substituted by the number "135" in the list in subsection 205 (3). </inglise>
<eesti>(3) Riigil&otilde;ivuseaduse (RT I 1997, 80, 1344; 2001, 55, 331; 56, 332; 64, 367; 65, 377) lisa 1 punkti 8 t&auml;iendatakse alapunktiga 53 j&auml;rgmises s&otilde;nastuses: </eesti>
<inglise>(3) Subclause 53 is added to clause 8) of Appendix 1 to the State Fees Act (RT I 1997, 80, 1344; 2001, 55, 331; 56, 332; 64, 367; 65, 377) worded as follows: </inglise>
<eesti>"53) Ravimiametile ravimi registreerimise taotluse esitamise eest 1000 krooni". </eesti>
<inglise>"53) for submission of an application for registration of a medicinal product to the Agency of Medicines, 1 000 kroons". </inglise>
<eesti>(4) Rahvatervise seaduse (RT I 1995, 57, 978; 1996, 3, 56; 49, 953; 1997, 37/38, 569; 1999, 30, 415; 88, 804; 2001, 23, 128) paragrahv 22 l&otilde;ige 4 tunnistatakse kehtetuks alates avaliku teenistuse seaduse (RT I 1995, 16, 228; 1999, 7, 112; 16, 271, 276) j&otilde;ustumisest. </eesti>
<inglise>(4) Subsection 22 (4) of the Public Health Act (RT I 1995, 57, 978; 1996, 3, 56; 49, 953; 1997, 37/38, 569; 1999, 30, 415; 88, 804; 2001, 23, 128) is repealed as of the entry into force of the Public Service Act (RT I 1995, 16, 228; 1999, 7, 112; 16, 271, 27). </inglise>
<eesti>&sect; 18. </eesti>
<inglise>&sect; 18. </inglise>
<eesti>Seaduse j&otilde;ustumine </eesti>
<inglise>Entry into force of Act </inglise>
<eesti>K&auml;esolev seadus j&otilde;ustub 1996. aasta 1. aprillil. </eesti>
<inglise>This Act enters into force on 1 April 1996. (1) RT = Riigi Teataja = State Gazette </inglise>
